Image 1 of 1
Survodutide 10 mg – Dual Glucagon and GLP-1 Receptor Research | Metabolic Signalling | Premium Research Compound
A premium research compound supplied in a convenient 10 mg vial.
Survodutide, also known by the development code BI 456906, is an investigational peptide studied for its dual activity at glucagon and glucagon-like peptide-1 receptors. It is investigated in laboratory and clinical research involving metabolic signalling, glucose regulation, energy expenditure, appetite-associated pathways, lipid metabolism, and liver-related metabolic processes.
What’s Included
1x Survodutide 10 mg vial
Over 99% Purity
Premium-quality research compound
Shipped from the Gold Coast, Queensland
Australia Post Express Post
Why Choose Survodutide 10 mg?
Survodutide is an engineered glucagon-based peptide designed to activate both the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R).
Researchers investigate Survodutide in relation to:
Dual GCGR and GLP-1R signalling
Glucose-regulation pathways
Insulin-associated signalling
Glucagon-receptor activity
Appetite and satiety mechanisms
Cellular-energy expenditure
Lipid-metabolism pathways
Liver-related metabolic signalling
Its balanced dual-receptor activity makes Survodutide an important compound for specialised metabolic, endocrine, cellular-energy, and receptor-signalling research.
Survodutide Research
Survodutide is commonly investigated in laboratory and clinical research relating to:
Glucagon-receptor activation
GLP-1 receptor activation
Dual-receptor pharmacology
Glucose-dependent insulin signalling
Glucagon-associated metabolic pathways
Appetite and food-intake regulation
Gastric-emptying mechanisms
Energy-expenditure pathways
Lipid metabolism
Adipose-tissue signalling
Liver-fat metabolism
Metabolic-stress responses
Research continues into how the combined activation of glucagon and GLP-1 receptors influences glucose regulation, energy balance, lipid processing, appetite-associated signalling, and liver metabolism.
Dual-Receptor Agonist Research
Survodutide is also identified by the research code BI 456906.
It is a modified glucagon-based peptide incorporating structural changes intended to support dual-receptor activity and extended experimental exposure.
Researchers investigate this specialised peptide for its potential to:
Activate both GCGR and GLP-1R pathways
Influence glucose-dependent endocrine signalling
Affect appetite-associated pathways
Modify cellular-energy expenditure
Support research into lipid mobilisation
Influence liver-related metabolic processes
Assist investigation of metabolic homeostasis
The GLP-1 receptor component is studied in relation to glucose-dependent insulin signalling, appetite regulation, and gastric-emptying pathways. The glucagon-receptor component is investigated for its potential influence on energy expenditure, lipid metabolism, and liver-associated metabolic activity.
Survodutide remains an investigational compound undergoing clinical research. Its safety and effectiveness have not been established for general human use in Australia.
Premium Research Compound. One Easy Order.
OZZ Peptides Survodutide 10 mg provides researchers with a convenient option for investigating dual GCGR/GLP-1R activity, metabolic signalling, cellular-energy regulation, and liver-related metabolic pathways.
Securely packed and shipped directly from the Gold Coast using Australia Post Express Post.
Product Highlights
🔄 Dual-Receptor Research
Investigated for combined activity at glucagon and GLP-1 receptors.
🧬 Glucagon-Based Peptide
An engineered peptide developed to support balanced dual-receptor pharmacology.
🔬 Metabolic-Signalling Research
Studied in relation to glucose regulation, endocrine activity, and metabolic homeostasis.
⚡ Cellular-Energy Research
Investigated in experimental studies involving energy-expenditure and fuel-utilisation pathways.
🧫 Liver-Metabolism Research
Studied in relation to liver-fat processing and metabolic-stress pathways.
🧠 Appetite-Pathway Research
Investigated in clinical research involving appetite, satiety, and food-intake signalling.
💎 Over 99% Purity
Premium-quality research compound.
📦 Fast Australian Delivery
Sent using Australia Post Express Post.
🌴 Gold Coast Based
Packed and shipped by the OZZ Peptides team in Queensland.
What You’ll Receive
1x Survodutide 10 mg vial
Securely packed for delivery
Australia Post Express Post
Storage
Store according to the storage information supplied with the product.
Before reconstitution, keep the vial in a cool, dry environment away from direct sunlight. After reconstitution, appropriate refrigerated storage may be required according to the supplier’s specifications and applicable laboratory protocol.
Important Information
Products supplied by OZZ Peptides are intended for laboratory research purposes only and are not intended for human consumption, injection, blood-glucose management, weight management, appetite suppression, metabolic enhancement, diagnosis, treatment, cure, or prevention of any disease.
Survodutide is an investigational research compound. It is not an approved medicine for general human use in Australia, and the safety, quality, and effectiveness of this research preparation have not been established.
A premium research compound supplied in a convenient 10 mg vial.
Survodutide, also known by the development code BI 456906, is an investigational peptide studied for its dual activity at glucagon and glucagon-like peptide-1 receptors. It is investigated in laboratory and clinical research involving metabolic signalling, glucose regulation, energy expenditure, appetite-associated pathways, lipid metabolism, and liver-related metabolic processes.
What’s Included
1x Survodutide 10 mg vial
Over 99% Purity
Premium-quality research compound
Shipped from the Gold Coast, Queensland
Australia Post Express Post
Why Choose Survodutide 10 mg?
Survodutide is an engineered glucagon-based peptide designed to activate both the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R).
Researchers investigate Survodutide in relation to:
Dual GCGR and GLP-1R signalling
Glucose-regulation pathways
Insulin-associated signalling
Glucagon-receptor activity
Appetite and satiety mechanisms
Cellular-energy expenditure
Lipid-metabolism pathways
Liver-related metabolic signalling
Its balanced dual-receptor activity makes Survodutide an important compound for specialised metabolic, endocrine, cellular-energy, and receptor-signalling research.
Survodutide Research
Survodutide is commonly investigated in laboratory and clinical research relating to:
Glucagon-receptor activation
GLP-1 receptor activation
Dual-receptor pharmacology
Glucose-dependent insulin signalling
Glucagon-associated metabolic pathways
Appetite and food-intake regulation
Gastric-emptying mechanisms
Energy-expenditure pathways
Lipid metabolism
Adipose-tissue signalling
Liver-fat metabolism
Metabolic-stress responses
Research continues into how the combined activation of glucagon and GLP-1 receptors influences glucose regulation, energy balance, lipid processing, appetite-associated signalling, and liver metabolism.
Dual-Receptor Agonist Research
Survodutide is also identified by the research code BI 456906.
It is a modified glucagon-based peptide incorporating structural changes intended to support dual-receptor activity and extended experimental exposure.
Researchers investigate this specialised peptide for its potential to:
Activate both GCGR and GLP-1R pathways
Influence glucose-dependent endocrine signalling
Affect appetite-associated pathways
Modify cellular-energy expenditure
Support research into lipid mobilisation
Influence liver-related metabolic processes
Assist investigation of metabolic homeostasis
The GLP-1 receptor component is studied in relation to glucose-dependent insulin signalling, appetite regulation, and gastric-emptying pathways. The glucagon-receptor component is investigated for its potential influence on energy expenditure, lipid metabolism, and liver-associated metabolic activity.
Survodutide remains an investigational compound undergoing clinical research. Its safety and effectiveness have not been established for general human use in Australia.
Premium Research Compound. One Easy Order.
OZZ Peptides Survodutide 10 mg provides researchers with a convenient option for investigating dual GCGR/GLP-1R activity, metabolic signalling, cellular-energy regulation, and liver-related metabolic pathways.
Securely packed and shipped directly from the Gold Coast using Australia Post Express Post.
Product Highlights
🔄 Dual-Receptor Research
Investigated for combined activity at glucagon and GLP-1 receptors.
🧬 Glucagon-Based Peptide
An engineered peptide developed to support balanced dual-receptor pharmacology.
🔬 Metabolic-Signalling Research
Studied in relation to glucose regulation, endocrine activity, and metabolic homeostasis.
⚡ Cellular-Energy Research
Investigated in experimental studies involving energy-expenditure and fuel-utilisation pathways.
🧫 Liver-Metabolism Research
Studied in relation to liver-fat processing and metabolic-stress pathways.
🧠 Appetite-Pathway Research
Investigated in clinical research involving appetite, satiety, and food-intake signalling.
💎 Over 99% Purity
Premium-quality research compound.
📦 Fast Australian Delivery
Sent using Australia Post Express Post.
🌴 Gold Coast Based
Packed and shipped by the OZZ Peptides team in Queensland.
What You’ll Receive
1x Survodutide 10 mg vial
Securely packed for delivery
Australia Post Express Post
Storage
Store according to the storage information supplied with the product.
Before reconstitution, keep the vial in a cool, dry environment away from direct sunlight. After reconstitution, appropriate refrigerated storage may be required according to the supplier’s specifications and applicable laboratory protocol.
Important Information
Products supplied by OZZ Peptides are intended for laboratory research purposes only and are not intended for human consumption, injection, blood-glucose management, weight management, appetite suppression, metabolic enhancement, diagnosis, treatment, cure, or prevention of any disease.
Survodutide is an investigational research compound. It is not an approved medicine for general human use in Australia, and the safety, quality, and effectiveness of this research preparation have not been established.